Patent ID: 10281478

Abstract:
Ischemia is treated to prevent or manage disease by delivering stem cells derived from cord blood and/or tissue. A patient suffering from disease caused in at least some part by ischemia is selected. At least one dose consisting of an effective amount of stem cells is administrated through intravenous (IV), intra thecal, intra-arterial, via catheter into the organ, via Myostar catheter into the heart, intracoronary, intrapericardial, and/or by direct injection into the organ. Effectiveness of the administration is monitored at selected time periods to determine whether there exists an improved clinical indication. A second dose is administered by a method that is at least invasive as that utilized in the prior dose, and the steps are repeated until the clinical indication shows improvement or until there is contraindication to continued treatment. Diseases include at least one of Ischemia, arteriosclerosis, complications of ischemia, decreased perfusion, aging or diabetes.